Ministry+of+SMEs+and+Startups
-
KAIST holds its first ‘KAIST Tech Fair’ in New York, USA
< Photo 1. 2023 KAIST Tech Fair in New York >
KAIST (President Kwang-Hyung Lee) announced on the 11th that it will hold the ‘2023 KAIST Tech Fair in New York’ at the Kimmel Center at New York University in Manhattan, USA, on the 22nd of this month. It is an event designed to be the starting point for KAIST to expand its startup ecosystem into the global stage, and it is to attract investments and secure global customers in New York by demonstrating the technological value of KAIST startup companies directly at location.
< Photo 2. President Kwang Hyung Lee at the 2023 KAIST Tech Fair in New York >
KAIST has been holding briefing sessions for technology transfer in Korea every year since 2018, and this year is the first time to hold a tech fair overseas for global companies.
KAIST Institute of Technology Value Creation (Director Sung-Yool Choi) has prepared for this event over the past six months with the Korea International Trade Association (hereinafter KITA, CEO Christopher Koo) to survey customer base and investment companies to conduct market analysis.
Among the companies founded with the technologies developed by the faculty and students of KAIST and their partners, 7 companies were selected to be matched with companies overseas that expressed interests in these technologies. Global multinational companies in the fields of IT, artificial intelligence, environment, logistics, distribution, and retail are participating as demand agencies and are testing the marketability of the start-up's technology as of September.
Daim Research, founded by Professor Young Jae Jang of the Department of Industrial and Systems Engineering, is a company specializing in smart factory automation solutions and is knocking on the door of the global market with a platform technology optimized for automated logistics systems.
< Photo 3. Presentation by Professor Young Jae Jang for DAIM Research >
It is a ‘collaborative intelligence’ solution that maximizes work productivity by having a number of robots used in industrial settings collaborate with one another. The strength of their solution is that logistics robots equipped with AI reinforced learning technology can respond to processes and environmental changes on their own, minimizing maintenance costs and the system can achieve excellent performance even with a small amount of data when it is combined with the digital twin technology the company has developed on its own.
A student startup, ‘Aniai’, is entering the US market, the home of hamburgers, with hamburger patty automation equipments and solutions. This is a robot kitchen startup founded by its CEO Gunpil Hwang, a graduate of KAIST’s School of Electrical Engineering which gathered together the experts in the fields of robot control, design, and artificial intelligence and cognitive technology to develop technology to automatically cook hamburger patties.
At the touch of a button, both sides of the patty are cooked simultaneously for consistent taste and quality according to the set condition. Since it can cook about 200 dishes in an hour, it is attracting attention as a technology that can not only solve manpower shortages but also accelerate the digital transformation of the restaurant industry.
Also, at the tech fair to be held at the Kimmel Center of New York University on the 22nd, the following startups who are currently under market verification in the U.S. will be participating: ▴'TheWaveTalk', which developed a water quality management system that can measure external substances and metal ions by transferring original technology from KAIST; ▴‘VIRNECT’, which helps workers improve their skills by remotely managing industrial sites using XR*; ▴‘Datumo’, a solution that helps process and analyze artificial intelligence big data, ▴‘VESSL AI’, the provider of a solution to eliminate the overhead** of machine learning systems; and ▴ ‘DolbomDream’, which developed an inflatable vest that helps the psychological stability of people with developmental disabilities.
* XR (eXtended Reality): Ultra-realistic technology that enhances immersion by utilizing augmented reality, virtual reality, and mixed reality technologies
** Overhead: Additional time required for stable processing of the program
In addition, two companies (Plasmapp and NotaAI) that are participating in the D-Unicorn program with the support of the Daejeon City and two companies (Enget and ILIAS Biologics) that are receiving support from the Scale Up Tips of the Ministry of SMEs and Startups, three companies (WiPowerOne, IDK Lab, and Artificial Photosynthesis Lab) that are continuing to realize the sustainable development goals for a total of 14 KAIST startups, will hold a corporate information session with about 100 invited guests from global companies and venture capital.
< Photo 4. Presentation for AP Lab >
Prior to this event, participating startups will be visiting the New York Economic Development Corporation and large law firms to receive advice on U.S. government support programs and on their attemps to enter the U.S. market. In addition, the participating companies plan to visit a startup support investment institution pursuing sustainable development goals and the Leslie eLab, New York University's one-stop startup support space, to lay the foundation for KAIST's leap forward in global technology commercialization.
< Photo 5. Sung-Yool Choi, the Director of KAIST Institute of Technology Value Creation (left) at the 2023 KAIST Tech Fair in New York with the key participants >
Sung-Yool Choi, the Director of KAIST Institute of Technology Value Creation, said, “KAIST prepared this event to realize its vision of being a leading university in creating global value.” He added, “We hope that our startups founded with KAIST technology would successfully completed market verification to be successful in securing global demands and in attracting investments for their endeavors.”
2023.09.11 View 9677 -
KAIST gearing up to train physician-scientists and BT Professionals joining hands with Boston-based organizations
KAIST (President Kwang Hyung Lee) announced on the 29th that it has signed MOUs with Massachusetts General Hospital, a founding member of the Mass General Brigham health care system and a world-class research-oriented hospital, and Moderna, a biotechnology company that developed a COVID-19 vaccine at the Langham Hotel in Boston, MA, USA on the morning of April 28th (local time). The signing ceremony was attended by officials from each institution joined by others headed by Minister LEE Young of the Korean Ministry of SMEs and Startups (MSS), and Commissioner LEE Insil of the Korean Intellectual Property Office.
< Photo 1. Photo from the Signing of MOU between KAIST-Harvard University Massachusetts General Hospital and KAIST-Moderna >
Mass General is the first and largest teaching hospital of Harvard Medical School in Boston, USA, and it is one of the most innovative hospitals in the world being the alma mater of more than 13 Nobel Prize winners and the home of the Mass General Research Institute, the world’s largest hospital-based research program that utilizes an annual research budget of more than $1.3 billion.
KAIST signed a general agreement to explore research and academic exchange with Mass General in September of last year and this MOU is a part of its follow-ups.
Mass General works with Harvard and the Massachusetts Institute of Technology (MIT), as well as local hospitals, to support students learn the theories of medicine and engineering, and gain rich clinical research experience.
Through this MOU, KAIST will explore cooperation with an innovative ecosystem created through the convergence of medicine and engineering. In particular, KAIST’s goal is to develop a Korean-style training program and implement a differentiated educational program when establishing the science and technology-oriented medical school in the future by further strengthening the science and engineering part of the training including a curriculum on artificial intelligence (AI) and the likes there of.
Also, in order to foster innovative physician-scientists, KAIST plans to pursue cooperation to develop programs for exchange of academic and human resources including programs for student and research exchanges and a program for students of the science and technology-oriented medical school at KAIST to have a chance to take part in practical training at Mass General.
David F.M. Brown, MD, Mass General President, said, “The collaboration with KAIST has a wide range of potentials, including advice on training of physician-scientists, academic and human resource exchanges, and vitalization of joint research by faculty from both institutions. Through this agreement, we will be able to actively contribute to global cooperation and achieve mutual goals.”
Meanwhile, an MOU between KAIST and Moderna was also held on the same day. Its main focus is to foster medical experts in cooperation with KAIST Graduate School of Medical Science and Engineering (GSMSE), and plans to cooperate in various ways in the future, including collaborating for development of vaccine and new drugs, virus research, joint mRNA research, and facilitation of technology commercialization.
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities. The Company has 48 programs in development across 45 development candidates, of which 38 are currently in active clinical trials.
“We are grateful to have laid a foundation for collaboration to foster industry experts with the Korea Advanced Institute of Science and Technology, a leader of science and technology innovation in Korea,” said Arpa Garay, Chief Commercial Officer, Moderna. “Based on our leadership and expertise in developing innovative mRNA vaccines and therapeutics, we hope to contribute to educating and collaborating with professionals in the bio-health field of Korea.“
President Kwang Hyung Lee of KAIST, said, “We deem this occasion to be of grave significance to be able to work closely with Massachusetts General Hospital, one of the world's best research-oriented hospitals, and Moderna, one of the most influential biomedical companies.”
President Lee continued, "On the basis of the collaboration with the two institutions, we will be able to bring up qualified physician-scientists and global leaders of the biomedical business who will solve problems of human health and their progress will in turn, accelerate the national R&D efforts in general and diversify the industry."
2023.04.29 View 10312